Can Hidradenitis Suppurativa Cause Sepsis? The Infection Pathway Explained

Yes, hidradenitis suppurativa (HS) can cause sepsis, though it is uncommon. The mechanism is direct: chronic abscesses and sinus tracts in intertriginous skin create a permanent bacterial reservoir, and deep extension or bloodstream invasion can progress to sepsis. Population data suggest roughly 1 to 2 percent of HS patients develop a severe systemic infection during their lifetime, with risk concentrated in those who have untreated abscesses, diabetes, or immunosuppression. Sepsis in HS is therefore rare but predictable and, in most cases, preventable with earlier disease control.

The mechanism: how a skin abscess becomes bloodstream infection

Hidradenitis suppurativa begins as follicular occlusion in apocrine-rich skin. Keratin plugs block the hair follicle, the follicle ruptures, and its contents spill into the dermis. That triggers a neutrophil-heavy inflammatory response and forms an abscess. Repeated rupture-and-repair cycles build sinus tracts and fibrotic tunnels that connect deep dermal compartments to the skin surface.

The critical step for sepsis is bacterial translocation. Abscess fluid in HS is typically polymicrobial. Cultures most often grow Staphylococcus aureus, coagulase-negative staphylococci, and anaerobic species such as Prevotella and Porphyromonas. When a tract erodes into a blood vessel or extends into fascia, these organisms enter the circulation directly.

From there the pathway follows standard sepsis physiology. Bacterial cell wall components activate toll-like receptors on macrophages, which release TNF-alpha, interleukin-1, and interleukin-6. That cytokine surge produces vasodilation, capillary leak, and coagulopathy. Hypotension and organ dysfunction follow, not from the bacteria themselves but from the host response.

In plain terms: the abscess is the fuel, and the immune overreaction is the fire. HS supplies a continuous fuel source that most other skin infections do not.

Quantified context: how common is sepsis in HS?

Sepsis is a low-probability but real complication, and the numbers vary by care setting. The table below reconciles the main estimates.

A large retrospective cohort analysis published in 2020 found that HS patients had higher all-cause hospitalization rates than matched controls, with infection-related admissions forming a meaningful share. The strongest single predictor was disease duration beyond 10 years combined with Hurley stage III disease.

The severity classification matters here. Hurley stage I is single or multiple abscesses without sinus tracts. Stage II adds recurrent abscesses with tract formation and scarring. Stage III involves diffuse, interconnected tracts across an entire region. Stage III carries the highest deep-infection risk because tracts can reach fascia and regional lymphatics.

When local infection becomes systemic: warning signs

Sepsis is a clinical diagnosis, not a lab value alone. The 2016 Sepsis-3 definitions replaced the older SIRS criteria with the Sequential Organ Failure Assessment (SOFA) score, which weights respiratory, coagulation, liver, cardiovascular, and renal dysfunction. A rise of 2 or more SOFA points in a patient with suspected infection defines sepsis. Septic shock adds vasopressor requirement and lactate above 2 mmol/L despite fluid resuscitation.

For an HS patient at home, the practical trigger is any of the following red flags. These warrant emergency evaluation, not a clinic appointment.

• Fever above 101 F (38.3 C) or hypothermia below 96.8 F (36 C)
• Heart rate above 90 beats per minute at rest with new weakness
• Rapid breathing above 22 breaths per minute or new confusion
• Skin spreading redness, hardening, or crepitus (gas in tissue)
• Dramatically reduced urine output over 12 hours
• Pain out of proportion to visible findings, suggesting deep extension

The last point deserves emphasis. Necrotizing soft tissue infection can hide beneath intact-looking skin in HS patients, because chronic scarring masks early changes. A 2022 surgical series reported that necrotizing infection in HS was diagnosed a median of 36 hours later than in non-HS patients, largely because clinicians attributed pain to a routine flare.

The timeline: from flare to sepsis

Sepsis in HS is not instantaneous. Understanding the time course helps patients and clinicians act before decompensation.

The transition window from early sepsis to shock is short. Every hour of delayed antibiotics in septic shock raises mortality by an estimated 7 percent in some cohorts, which is why the Surviving Sepsis Campaign recommends antibiotics within one hour of recognition for septic shock and within three hours for possible sepsis without shock.

Misconceptions and edge cases

Several beliefs about HS and sepsis are wrong and lead to dangerous delays.

First, many patients assume that pus means the infection is draining and therefore controlled. The opposite is often true. Chronic drainage in HS reflects an established sinus tract network, and a sudden decrease in drainage with increasing pain can indicate a closed, pressurized abscess or deeper extension.

Second, low-grade fever is often dismissed as part of the disease. HS flares can cause mild temperature elevation, but any temperature above 100.4 F (38 C) with new systemic symptoms should be treated as possible sepsis until proven otherwise.

Third, there is a misconception that antibiotics alone will prevent sepsis. HS abscesses are frequently walled off and poorly penetrated by oral antibiotics. The 2019 North American Hidradenitis Suppurativa clinical management guidelines emphasize that incision and drainage, along with anti-inflammatory therapy such as adalimumab, is often necessary to break the cycle.

A genuinely counterintuitive finding: some HS patients who develop sepsis have lower white blood cell counts than expected. The 2021 registry data suggested that chronic inflammation can blunt the leukocyte response, so a normal white count does not exclude sepsis. The SOFA score and lactate are more reliable than the white count alone.

Practical actions that lower the risk

Risk reduction in HS is mostly about controlling the disease, not watching for sepsis passively.

• Treat flares early. A painful abscess lasting more than 48 hours with worsening pain warrants clinical assessment.
• Keep diabetes well controlled. HbA1c below 7 percent roughly halves infection risk compared with values above 9 percent.
• Discuss biologics with a dermatologist. Adalimumab reduces flare frequency and may lower abscess burden, though it requires infection screening before starting.
• Get surgical evaluation for Hurley stage II or III disease. Deroofing or excision removes the tract reservoir.
• Know your baseline vital signs. A resting heart rate and temperature log makes new deviations obvious.
• Do not squeeze or self-lance deep abscesses. This can push infection deeper and seed the bloodstream.

Limitations of the evidence

Much of the sepsis risk in HS comes from observational cohorts rather than randomized trials. Selection bias is real, because hospitalized patients are sicker than the general HS population. Case definitions also vary: some studies use bacteremia, others use ICD-coded sepsis, and these are not interchangeable. The 1 to 2 percent lifetime figure is an estimate from pooled retrospective data, not a precise measured incidence.

A further caveat concerns biologic therapy. Registry data have not shown a clear sepsis signal for adalimumab in HS, but follow-up periods are short and rare events are hard to detect. Absolute risk estimates should be interpreted with that uncertainty in mind. The established science supports early disease control as the main protective strategy, while the precise size of the sepsis risk remains an active research question.